Roxane Agrees To Hold Off On Generic Asacol

Law360, New York (March 12, 2010, 1:52 PM EST) -- Roxane Laboratories Inc. has agreed to delay its launch of a generic version of inflammatory bowel drug Asacol until as late as November as part of a discovery agreement in a patent infringement suit brought by Procter & Gamble Pharmaceuticals Inc. and Medeva Pharma Suisse AG.

Roxane filed a stipulation Thursday in the U.S. District Court for the District of New Jersey agreeing not to sell the drug before Nov. 1 or “the date of favorable judgment, whichever is earlier,” even though the U.S. Food and...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.